SABS News and Press, SAB Biotherapeutics Inc. From 10/24/23

2023-10-24 08:00:12 ET More on SAB Biotherapeutics SAB Biotherapeutics GAAP EPS of -$0.14 Seeking Alpha’s Quant Rating on SAB Biotherapeutics Historical earnings data for SAB Biotherapeutics For further details see: SAB Biotherapeutics gets new fin...

SIOUX FALLS, S.D., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics , Inc. (Nasdaq: SABS ), today announced that Michael G. King Jr. has been named Chief Financial Officer. SAB is a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a fully-h...

Australian Human Research Ethics Committee (HREC) grants approval for SAB to begin first-in-human Phase 1 clinical study of SAB-142, the first fully human anti-thymocyte immunoglobulin (ATG) SAB-142 directly targets multiple immune cells involved in destroying insulin-producing pancreatic...

2023-10-02 08:17:26 ET More on SAB Biotherapeutics SAB Biotherapeutics GAAP EPS of -$0.14 Seeking Alpha’s Quant Rating on SAB Biotherapeutics Historical earnings data for SAB Biotherapeutics Financial information for SAB Biotherapeutics For fur...

Funding to support clinical advancement of SAB-142, a potential disease-modifying treatment Financing led by RA Capital Management, with participation from BVF Partners, Sessa Capital, Commodore Capital, RTW Investments, Marshall Wace, and the JDRF T1D Fund SIO...

2023-08-22 05:21:59 ET More on SAB Biotherapeutics SAB Bio posts positive data from phase 3 trial of SAB-185 in patients with COVID-19 SAB Biotherapeutics surges ~85% on FDA fast track tag for influenza drug SAB-176 SAB Biotherapeutics gets additional $8.2M in fundin...

SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (hIgG), also known as fully-human...

SAB highlights results from GLP toxicology study confirming SAB-142's mechanism of action at the 23rd Federation of Clinical Immunology Societies (FOCIS) Study shows SAB’s fully-human multi-target immune modulating therapeutic for treatment of Type 1 Diabetes is well tolerated ...

SIOUX FALLS, S.D., May 30, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG) antibodies (fully-human polyc...

SIOUX FALLS, S.D., May 19, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (hIgG), also known as fully-human polyclon...